Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor-Reference-Cited by-同舟云学术

Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor

Published:2010-09 Issue:9 Volume:34 Page:e237-e239
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Yamaguchi Masaki,Munemoto Saori,Kasada Atsuo,Murata Ryoichi,Ueda Mikio

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference9 articles.

1. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia;Kantarjian;N Engl J Med,2002

2. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study;Sawyers;Blood,2002

3. Chronic myelogenous leukemia: biology and therapy;Faderl;Ann Intern Med,1999

4. Chronic myelogenous leukemia terminating in acute megakaryoblastic leukemia. Case report;Bourantas;J Exp Clin Cancer Res,1998

5. Extramedullary disease in Ph-positive chronic myelogenous leukemia: frequency, clinical features and prognostic significance;Inverardi;Haematologica,1990

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dasatinib;Reactions Weekly;2021-07

2. 18FDG-PET/CT: 21st century approach to leukemic tumors in 124 cases;American Journal of Hematology;2016-02-09

3. Marked regression of myelofibrosis during reduced-dose dasatinib treatment in chronic myelogenous leukemia in accelerated phase;Leukemia & Lymphoma;2015-07-21

4. Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy;Clinical Medicine Insights: Oncology;2010-01